A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis

Ublituximab, a novel monoclonal antibody (mAb) targeting a unique epitope on the CD20 antigen, is glycoengineered for enhanced B-cell targeting through antibody-dependent cellular cytotoxicity (ADCC). Greater ADCC may allow lower doses and shorter infusion times versus other anti-CD20 mAbs. The obje...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Multiple sclerosis Ročník 27; číslo 3; s. 420
Hlavní autori:	Fox, Edward, Lovett-Racke, Amy E, Gormley, Matthew, Liu, Yue, Petracca, Maria, Cocozza, Sirio, Shubin, Richard, Wray, Sibyl, Weiss, Michael S, Bosco, Jenna A, Power, Sean A, Mok, Koby, Inglese, Matilde
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	England 01.03.2021
Predmet:	gadolinium-enhancing lesions magnetic resonance imaging relapse multiple sclerosis TG-1101 Ublituximab
ISSN:	1477-0970, 1477-0970
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!